Antosplatinib and Landerplenib - What's the Cure Rate?

Antosplatinib is a sick tyrosine kinase inhibitor. Wenerplenib, which they showed in preclinical studies, was useful as a single agent and mixed well with a number of phonetic lacs in the right subtype genetically. Eventually there'll be a threin 7 plus men inhibitor versus threin7 trials we just talked about. So it's getting to be a busy AML subtype.